Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | DRIO | Common Stock | Sale | -$578K | -30.5K | -3.47% | $18.96* | 847K | Nov 3, 2021 | Direct | F1, F2 |
transaction | DRIO | Common Stock | Sale | -$145K | -7.86K | -0.93% | $18.49* | 839K | Nov 4, 2021 | Direct | F1, F3 |
holding | DRIO | Common Stock | 37.9K | Nov 3, 2021 | By Dicilyon Consulting and Investment Ltd. | F4 |
Id | Content |
---|---|
F1 | The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2021. |
F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.38, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2). |
F3 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.02 to $19.10, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3). |
F4 | The amount shown represents the beneficial ownership of the issuer's securities held by Dicilyon Consulting and Investment Ltd. which may be deemed to be attributable to Mr. Raphael because Mr. Raphael possesses voting and dispositive power over the securities held by Dicilyon Consulting and Investment Ltd. by virtue of a proxy. Mr. Raphael disclaims beneficial ownership of the securities set forth herein. |